Indole-3-propionic acid as a mechanistic bridge between pain tolerance and epigenetic aging
Background
Chronic pain sensitivity correlates with accelerated epigenetic aging, as shown by increased DNAmPhenoAge (β=0.225) and DNAmGrimAge (β=0.198) per unit of pain intensity [journals.sagepub.com/doi/10.1177/17448069221118004]. Reduced heat and pressure pain thresholds associate with older epigenetic age (r=−0.478 and r=−0.571) [pmc.ncbi.nlm.nih.gov/articles/PMC6710702]. Meanwhile, gut‑derived tryptophan metabolites, particularly indole‑3‑propionic acid (IPA), can suppress microglial inflammation via aryl hydrocarbon receptor (AhR) signaling [pmc.ncbi.nlm.nih.gov/articles/PMC12515389]. Age‑related dysbiosis diminishes IPA‑producing Firmicutes while expanding pro‑inflammatory Proteobacteria [www.aging-us.com/article/202525/text]. No study has yet tested whether IPA levels mediate the link between pain tolerance and epigenetic age.
Hypothesis
Higher fecal IPA concentrations predict greater pain tolerance (higher heat and pressure thresholds) and lower epigenetic age acceleration, independent of chronic pain status. Conversely, low IPA reflects microglial hyperreactivity, lowered pain thresholds, and accelerated DNAmPhenoAge/GrimAge.
Mechanistic Model
- Microbial source: Clostridium sporogenes and related taxa convert dietary tryptophan to IPA in the colon.
- Systemic circulation: IPA crosses the gut barrier and blood‑brain barrier via passive diffusion.
- Central action: IPA binds neuronal and microglial AhR, promoting anti‑inflammatory transcriptional programs (e.g., increased IL‑10, reduced NLRP3 inflammasome activity).
- Pain modulation: Reduced microglial proinflammatory signaling lowers central sensitization, raising pain thresholds.
- Epigenetic impact: AhR activation influences NAD+‑dependent sirtuin activity and histone deacetylation, slowing age‑related DNA methylation drift captured by PhenoAge/GrimAge clocks.
Predictions
- Positive correlation: Fecal IPA levels will positively correlate with heat pain threshold (HPT) and pressure pain threshold (PPT) at the trapezius (expected r > 0.4).
- Negative correlation: IPA levels will negatively correlate with DNAmPhenoAge and DNAmGrimAge acceleration (expected β < −0.2 per SD increase in IPA).
- Mediation: The effect of IPA on epigenetic age will be mediated by pain tolerance (significant indirect effect in mediation analysis).
- Intervention: Oral IPA supplementation (10 mg/kg/day for 8 weeks) will increase HPT/PPT and reduce epigenetic age acceleration compared with placebo, independent of changes in self‑reported chronic pain.
Experimental Design
- Cohort: Recruit n=200 adults aged 40‑70, stratified by pain status (no pain, mild chronic pain, moderate chronic pain) to ensure variability.
- Baseline measures: Collect stool for IPA quantification (LC‑MS/MS), perform quantitative sensory testing (HPT, PPT), draw blood for DNAmPhenoAge and DNAmGrimAge, and administer questionnaires (Pain Catastrophizing Scale, IBD‑Q).
- Analysis: Use linear regression adjusting for age, sex, BMI, diet (tryptophan intake), and medication. Test mediation with bootstrap (5 000 samples).
- Intervention arm: Randomized, double‑blind, placebo‑controlled trial of IPA vs. maltodextrin for 8 weeks; repeat primary outcomes post‑treatment.
Potential Confounders & Mitigation
- Dietary tryptophan: Control via 24‑h recalls and include as covariate.
- Gut permeability: Measure serum zonulin to adjust for leaky‑gut effects on IPA absorption.
- Microbiota composition: Perform 16S rRNA sequencing to confirm IPA‑producer abundance.
- Systemic inflammation: Include plasma IL‑6, CRP as covariates.
Implications
If validated, IPA would serve as a biologically actionable biomarker linking gut microbiome health, pain perception, and aging. This could accelerate development of microbiome‑targeted interventions (prebiotics, probiotics, or direct IPA supplementation) that simultaneously improve pain resilience and delay epigenetic aging, offering a simple, non‑invasive complement to current epigenetic clocks.